View Future GrowthEpigenomics 과거 순이익 실적과거 기준 점검 0/6Epigenomics은 연평균 25.8%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 55.4%의 비율로 감소했습니다.핵심 정보25.80%순이익 성장률47.37%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률-55.44%자기자본이익률-15,700.00%순이익률-1,308.33%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트공시 • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.공시 • Nov 09+ 2 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023모든 업데이트 보기Recent updates공시 • Apr 21Epigenomics AG, Annual General Meeting, May 27, 2026Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time.공시 • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026공시 • Jul 17Epigenomics AG, Annual General Meeting, Aug 27, 2025Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time.New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.7m free cash flow). Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$365k). Market cap is less than US$10m (€1.43m market cap, or US$1.54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€500k net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).New Risk • Mar 24New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€8.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$367k). Market cap is less than US$10m (€1.57m market cap, or US$1.69m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€5.7m). Currently unprofitable and not forecast to become profitable over next 2 years (€600k net loss in 2 years). Shareholders have been diluted in the past year (6.3% increase in shares outstanding).New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (€447k revenue, or US$484k). Market cap is less than US$10m (€1.41m market cap, or US$1.52m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€14m). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€595k net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding).공시 • Nov 29+ 2 more updatesEpigenomics AG, Annual General Meeting, May 29, 2024Epigenomics AG, Annual General Meeting, May 29, 2024.공시 • Oct 12New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion. TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023.Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.Buying Opportunity • Aug 03Now 29% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.공시 • Jul 26New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.Buying Opportunity • Jul 19Now 24% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.공시 • Jun 13Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5mEpigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development.Price Target Changed • Jun 02Price target increased by 9.1% to €6.00Up from €5.50, the current price target is provided by 1 analyst. New target price is 926% above last closing price of €0.58. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €1.63 next year compared to a net loss per share of €2.96 last year.Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.공시 • May 20Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place.Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.Breakeven Date Change • Dec 22No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €25.8m in 2024.Breakeven Date Change • Nov 16No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.공시 • Nov 09+ 2 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023Reported Earnings • Aug 15Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €126.0k (up 7.7% from 2Q 2021). Net loss: €1.30m (loss narrowed 44% from 2Q 2021). Over the next year, revenue is expected to shrink by 91% compared to a 12% growth forecast for the Biotechs industry in Germany.Price Target Changed • Jun 01Price target increased to €1.07Up from €0.95, the current price target is an average from 2 analysts. New target price is 117% above last closing price of €0.49. Stock is down 72% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €0.22 last year.Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: €0.17 loss per share. Revenue: €115.0k (up 8.5% from 1Q 2021). Net loss: €2.66m (loss widened 121% from 1Q 2021). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 91% compared to a 36% growth forecast for the industry in Germany.Price Target Changed • Apr 27Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 106% above last closing price of €0.46. Stock is down 63% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.Breakeven Date Change • Apr 06No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.Price Target Changed • Mar 28Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 77% above last closing price of €0.54. Stock is down 79% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.Price Target Changed • Jan 23Price target decreased to €1.14Down from €1.39, the current price target is an average from 2 analysts. New target price is 122% above last closing price of €0.51. Stock is down 80% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €2.02 last year.Is New 90 Day High Low • Mar 07New 90-day low: €2.19The company is down 39% from its price of €3.57 on 07 December 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.33 per share.Is New 90 Day High Low • Jan 31New 90-day low: €2.27The company is down 53% from its price of €4.80 on 02 November 2020. The German market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.76 per share.Price Target Changed • Dec 16Price target lowered to €23.73Down from €32.80, the current price target is an average from 3 analysts. The new target price is 638% above the current share price of €3.22. As of last close, the stock is down 71% over the past year.매출 및 비용 세부 내역Epigenomics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:ECX 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 25000030 Sep 250-20030 Jun 250-30031 Mar 250-30031 Dec 240-30030 Sep 2400-1-130 Jun 2403-2-131 Mar 24010-131 Dec 230-44030 Sep 231-183-430 Jun 230-1610531 Mar 231-159631 Dec 221-173030 Sep 221-77630 Jun 226-38531 Mar 226-48431 Dec 216-28330 Sep 216-38230 Jun 211-96231 Mar 211-107331 Dec 201-127430 Sep 201-168530 Jun 201-168631 Mar 201-179731 Dec 191-179730 Sep 191-1410830 Jun 191-1410731 Mar 192-129631 Dec 182-139630 Sep 182-118630 Jun 182-107531 Mar 182-118531 Dec 172-108430 Sep 173-98430 Jun 173-1010431 Mar 174-99431 Dec 164-1110530 Sep 163-119530 Jun 163-119531 Mar 162-107631 Dec 152-95630 Sep 152-116730 Jun 152-1056양질의 수익: ECX 은(는) 현재 수익성이 없습니다.이익 마진 증가: ECX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ECX는 수익성이 없지만 지난 5년 동안 연평균 25.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ECX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ECX은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(45%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ECX는 현재 수익성이 없으므로 자본 수익률이 음수(-15700%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 14:00종가2026/05/21 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Epigenomics AG는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hans Bjorn BostromEdison Investment ResearchSimon ScholesFirst Berlin Equity Research GmbHBryan BrokmeierMaxim Group2명의 분석가 더 보기
공시 • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026
Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.
공시 • Nov 09+ 2 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023
공시 • Apr 21Epigenomics AG, Annual General Meeting, May 27, 2026Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time.
공시 • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026
공시 • Jul 17Epigenomics AG, Annual General Meeting, Aug 27, 2025Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time.
New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.7m free cash flow). Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$365k). Market cap is less than US$10m (€1.43m market cap, or US$1.54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€500k net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).
New Risk • Mar 24New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€8.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$367k). Market cap is less than US$10m (€1.57m market cap, or US$1.69m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€5.7m). Currently unprofitable and not forecast to become profitable over next 2 years (€600k net loss in 2 years). Shareholders have been diluted in the past year (6.3% increase in shares outstanding).
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (€447k revenue, or US$484k). Market cap is less than US$10m (€1.41m market cap, or US$1.52m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€14m). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€595k net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding).
공시 • Nov 29+ 2 more updatesEpigenomics AG, Annual General Meeting, May 29, 2024Epigenomics AG, Annual General Meeting, May 29, 2024.
공시 • Oct 12New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion. TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023.
Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
Buying Opportunity • Aug 03Now 29% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.
공시 • Jul 26New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.
Buying Opportunity • Jul 19Now 24% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.
공시 • Jun 13Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5mEpigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development.
Price Target Changed • Jun 02Price target increased by 9.1% to €6.00Up from €5.50, the current price target is provided by 1 analyst. New target price is 926% above last closing price of €0.58. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €1.63 next year compared to a net loss per share of €2.96 last year.
Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
공시 • May 20Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place.
Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.
Breakeven Date Change • Dec 22No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €25.8m in 2024.
Breakeven Date Change • Nov 16No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.
Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.
공시 • Nov 09+ 2 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023
Reported Earnings • Aug 15Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €126.0k (up 7.7% from 2Q 2021). Net loss: €1.30m (loss narrowed 44% from 2Q 2021). Over the next year, revenue is expected to shrink by 91% compared to a 12% growth forecast for the Biotechs industry in Germany.
Price Target Changed • Jun 01Price target increased to €1.07Up from €0.95, the current price target is an average from 2 analysts. New target price is 117% above last closing price of €0.49. Stock is down 72% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €0.22 last year.
Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: €0.17 loss per share. Revenue: €115.0k (up 8.5% from 1Q 2021). Net loss: €2.66m (loss widened 121% from 1Q 2021). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 91% compared to a 36% growth forecast for the industry in Germany.
Price Target Changed • Apr 27Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 106% above last closing price of €0.46. Stock is down 63% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.
Breakeven Date Change • Apr 06No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.
Price Target Changed • Mar 28Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 77% above last closing price of €0.54. Stock is down 79% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.
Price Target Changed • Jan 23Price target decreased to €1.14Down from €1.39, the current price target is an average from 2 analysts. New target price is 122% above last closing price of €0.51. Stock is down 80% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €2.02 last year.
Is New 90 Day High Low • Mar 07New 90-day low: €2.19The company is down 39% from its price of €3.57 on 07 December 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.33 per share.
Is New 90 Day High Low • Jan 31New 90-day low: €2.27The company is down 53% from its price of €4.80 on 02 November 2020. The German market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.76 per share.
Price Target Changed • Dec 16Price target lowered to €23.73Down from €32.80, the current price target is an average from 3 analysts. The new target price is 638% above the current share price of €3.22. As of last close, the stock is down 71% over the past year.